Smith Karen L.
CIK 0001639637
Chief Medical OfficerDirector
Filings
21
Latest Apr 2, 2026
Issuers covered
7
Showing
21 of 21
Page 1
Track record
1 of 1 open-market trades scored (100% price coverage). Returns are signed: a +10% move on a sale shows as -10% (insider was wrong).
| Horizon | Trades | Win rate | Avg | Median | Best | Worst |
|---|---|---|---|---|---|---|
| 30 days | 1 | 0% | -19.1% | -19.1% | -19.1% | -19.1% |
| 90 days | 1 | 100% | +6.1% | +6.1% | +6.1% | +6.1% |
| 180 days | 1 | 100% | +4.4% | +4.4% | +4.4% | +4.4% |
| 365 days | 1 | 0% | -84.7% | -84.7% | -84.7% | -84.7% |
Issuers
Companies where Smith Karen L. has filed
| Ticker | Issuer | Filings | Last filed |
|---|---|---|---|
| SKYE | Skye Bioscience, Inc. | 5 | Apr 2, 2026 |
| SGMO | Sangamo Therapeutics, Inc | 4 | Jun 16, 2025 |
| AUPH | Aurinia Pharmaceuticals Inc. | 3 | Nov 25, 2024 |
| QNCX | Quince Therapeutics, Inc. | 3 | Feb 2, 2023 |
| TRML | Tourmaline Bio, Inc. | 3 | Jun 14, 2023 |
| CNTX | Context Therapeutics Inc. | 2 | Jun 12, 2025 |
| ATRS | Antares Pharma, Inc. | 1 | May 26, 2022 |
All filings
21 Form 4 / 4-A filings, newest first
| Filed | Top transaction | Shares | Price | Value | ||
|---|---|---|---|---|---|---|